Liquidia (NASDAQ:LQDA – Get Free Report) and Codexis (NASDAQ:CDXS – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.
Institutional & Insider Ownership
64.5% of Liquidia shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Liquidia and Codexis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Liquidia | 7.74% | 46.82% | 7.06% |
| Codexis | -40.97% | -68.09% | -23.72% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Liquidia | 2 | 0 | 6 | 3 | 2.91 |
| Codexis | 1 | 0 | 1 | 0 | 2.00 |
Liquidia currently has a consensus price target of $55.63, suggesting a potential downside of 13.10%. Codexis has a consensus price target of $5.00, suggesting a potential upside of 102.43%. Given Codexis’ higher possible upside, analysts plainly believe Codexis is more favorable than Liquidia.
Risk & Volatility
Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.48, indicating that its share price is 148% more volatile than the S&P 500.
Earnings & Valuation
This table compares Liquidia and Codexis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Liquidia | $158.32 million | 35.96 | -$68.92 million | $0.14 | 457.21 |
| Codexis | $70.39 million | 3.19 | -$43.97 million | ($0.37) | -6.68 |
Codexis has lower revenue, but higher earnings than Liquidia. Codexis is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Summary
Liquidia beats Codexis on 11 of the 15 factors compared between the two stocks.
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
